NovaBay Pharmaceuticals Statistics
Total Valuation
NBY has a market cap or net worth of $42.33 million. The enterprise value is $35.69 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NBY has 26.63 million shares outstanding. The number of shares has increased by 757.14% in one year.
| Current Share Class | 26.63M |
| Shares Outstanding | 26.63M |
| Shares Change (YoY) | +757.14% |
| Shares Change (QoQ) | +1,591.51% |
| Owned by Insiders (%) | 47.47% |
| Owned by Institutions (%) | 5.34% |
| Float | 2.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 2.68 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.86 |
| P/OCF Ratio | 15.86 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 13.20 |
Financial Position
The company has a current ratio of 7.60
| Current Ratio | 7.60 |
| Quick Ratio | 6.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.29 |
| Interest Coverage | -27.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -76.11% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -96.10% |
| Weighted Average Cost of Capital (WACC) | 5.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.54M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.64% in the last 52 weeks. The beta is 0.20, so NBY's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -45.64% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 9.63 |
| Relative Strength Index (RSI) | 38.74 |
| Average Volume (20 Days) | 675,617 |
Short Selling Information
The latest short interest is 333,120, so 1.25% of the outstanding shares have been sold short.
| Short Interest | 333,120 |
| Short Previous Month | 767,854 |
| Short % of Shares Out | 1.25% |
| Short % of Float | 12.69% |
| Short Ratio (days to cover) | 0.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.59M |
| Pretax Income | -33.22M |
| Net Income | -22.14M |
| EBITDA | -7.58M |
| EBIT | -7.59M |
| Earnings Per Share (EPS) | -$3.80 |
Full Income StatementBalance Sheet
The company has $7.96 million in cash and $776,000 in debt, with a net cash position of $7.18 million or $0.27 per share.
| Cash & Cash Equivalents | 7.96M |
| Total Debt | 776,000 |
| Net Cash | 7.18M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | -22.83M |
| Book Value Per Share | -0.92 |
| Working Capital | 7.53M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.70M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 6,667 |
| Net Borrowing | -500,000 |
| Free Cash Flow | 2.70M |
| FCF Per Share | $0.10 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
